M. Ott

发表

Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

F. Marmé, M. Hennig, D. Seimetz, 2011, International journal of cancer.

Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy.

C. von Kalle, A. Fischer, Claudia Cattoglio, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma.

J. Tabernero, J. Soria, L. Paz-Ares, 2014, European journal of cancer.

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma

F. Feuerhake, M. McGurk, J. Soria, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Peripheral natural killer cell activity and intraperitoneal soluble p55 tumor necrosis factor receptor in patients with malignant ascites: two possible indicators for response to intraperitoneal combined tumor necrosis factor α and interferon γ treatment

U. Raeth, D. Männel, H. Gallati, 1996, Cancer Immunology, Immunotherapy.

Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1

Yang Du, Manuel Grez, Hanno Glimm, 2006, Nature Medicine.

Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease

Hans Martin, Barbara Burwinkel, Rongxi Yang, 2010, Nature Medicine.

Advances in the treatment of Chronic Granulomatous Disease by gene therapy.

M. Grez, D. Hoelzer, R. Seger, 2007, Current gene therapy.

MDM2 inhibition: an important step forward in cancer therapy

M. Konopleva, M. Andreeff, G. Martinelli, 2020, Leukemia.

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

M. Konopleva, J. Cavenagh, G. Martinelli, 2022, Blood advances.

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

M. Konopleva, M. Andreeff, S. Paolini, 2022, Blood.

Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.

W. Pierceall, G. Martinelli, B. Higgins, 2020, Leukemia research.

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.

F. Feuerhake, M. McGurk, J. Soria, 2017 .

Progress and prospects: gene therapy clinical trials (part 1) (vol 14, pg 1439, 2007)

R. Ali, J. Bainbridge, T. Flotte, 2007 .

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

M. Konopleva, M. Andreeff, S. Paolini, 2019, Blood.

Mobilization and transduction of CD34(+) peripheral blood stem cells in patients with X-linked chronic granulomatous disease.

M. Grez, O. Ottmann, D. Hoelzer, 2002, Journal of hematotherapy & stem cell research.

The trifunctional antibody catumaxomab: Correlation between immunological response and clinical outcome--New analysis of a pivotal phase II/III study.

M. Hennig, D. Seimetz, H. Lindhofer, 2010 .

Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells.

A. Ganser, M. Dinauer, M. Grez, 1998, Human gene therapy.

Update on gene therapy for chronic granulomatous disease

A. Jauch, B. Burwinkel, A. Thrasher, 2007 .